Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL von Hill, LaQuisa C, Rouce, Rayne H, Smith, Tyler S, Boriskie, Blakely, Srinivasan, Madhuwanti, Thakkar, Sachin G, Zhang, Huimin, Mehta, Birju, Sritabal-Ramirez, Juntima, Grilley, Bambi J, Heslop, Helen E, Brenner, Malcolm K, Mamonkin, Maksim

Volltext

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma von Rouce, Rayne H., Hill, LaQuisa C., Smith, Tyler S., Yang, Lina, Boriskie, Blakely, Srinivasan, Madhuwanti, Zhang, Huimin, Perconti, Silvana, Mehta, Birju, Dakhova, Olga, Grilley, Bambi J., Heslop, Helen E., Brenner, Malcolm K., Mamonkin, Maksim

Volltext